Joe Markson
Principal at Novo Holdings
San Francisco, California
Overview
Work Experience
Principal
2024 - Current
Senior Associate, Venture Investments
2022 - 2024
Associate, Ventures Investments
2020 - 2021
Board Observer
2023
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Raised $114,000,000.00 from California Institute for Regenerative Medicine and California Institute for Regenerative Medicine.
Director Board of Directors
2023
Board Observer
2021
Board Observer
2020 - 2021
Board Observer from Novo Ventures' Series B investment through Reneo's IPO (NASDAQ: RPHM).
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Raised $220,000,000.00 from Pappas Capital, New Enterprise Associates, Lundbeckfonden Ventures, Abingworth, Amzak Health Investors, Chiesi Ventures, RiverVest, Rock Springs Capital, Aisling Capital and Novo Ventures.
Strategy Lead
2020 - 2020
Technology development strategy
Portfolio Manager (consultant)
2020 - 2020
Strategic R&D portfolio planning
Aria Pharmaceuticals is a artificial intelligence-driven biopharmaceutical company.
Raised $14,300,000.00 from Future Planet Capital, Silicon Valley Syndicate Club and Network.VC.
Consultant
2018 - 2020
Management consultant working exclusively in BCG's Healthcare and PIPE (Principle Investor / Private Equity) practices. Extensive experience across the healthcare spectrum - from R&D strategy and portfolio evaluation for biopharma clients, to medtech and biopharma manufacturing, to insurance claims data analysis. Also extensive experience with buy-side due diligence work for both private equity and strategic buyer clients across a variety of industries (healthcare software, financial services, Internet of Things). Projects have included: -R&D strategy refresh for the head of R&D at a biopharma client -R&D portfolio evaluation and rationalization for a biopharma client -Planning for manufacturing insourcing at a Medtech client -Design and business case for a digital transformation of manufacturing at a Biopharma client -Patient segmentation and opportunity identification based on analysis of hundreds of millions of health insurance claims data for an insurer -Due diligence projects: 4 buy-side due diligences across healthcare software, financial services, and Internet of Things
BCG Securities focuses on wealth management with high net worth individuals.
Postdoctoral Scholar
2013 - 2018
Postdoc with Michael Elowitz, pioneer in systems and synthetic biology. I used synthetic and systems biology approaches to studying development. I employed both experimental and computational techniques, including timelapse fluorescence microscopy, mammalian cell culture and genetic engineering, flow cytometry, dynamical systems modeling, parameter estimation, analysis of timelapse microscopy data.
Postdoctoral associate
2010 - 2013
Continuation of my PhD research in the O'Shea lab